Envista (NYSE:NVST) Given New $19.00 Price Target at JPMorgan Chase & Co.

Envista (NYSE:NVST) had its price objective dropped by investment analysts at JPMorgan Chase & Co. from $20.00 to $19.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 5.97% from the stock’s previous close.

NVST has been the topic of several other research reports. Wells Fargo & Company lifted their target price on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 6th. Piper Sandler upped their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Mizuho began coverage on shares of Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 target price on the stock. Jefferies Financial Group upped their price target on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Finally, Morgan Stanley reduced their price objective on Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.38.

Envista Price Performance

NYSE:NVST traded down $0.31 during trading hours on Thursday, reaching $17.93. 636,254 shares of the company were exchanged, compared to its average volume of 2,247,984. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The firm has a market cap of $3.09 billion, a PE ratio of -2.76, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista has a twelve month low of $15.15 and a twelve month high of $23.00. The stock’s 50-day moving average is $20.27 and its 200-day moving average is $19.69.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, sell-side analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NVST. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Envista by 11.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,314 shares of the company’s stock worth $303,000 after acquiring an additional 1,538 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Envista by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 19,887 shares of the company’s stock worth $392,000 after purchasing an additional 1,355 shares in the last quarter. US Bancorp DE boosted its position in shares of Envista by 150.6% during the third quarter. US Bancorp DE now owns 4,971 shares of the company’s stock worth $98,000 after buying an additional 2,987 shares during the period. Assetmark Inc. grew its stake in shares of Envista by 5.9% in the third quarter. Assetmark Inc. now owns 38,641 shares of the company’s stock valued at $764,000 after buying an additional 2,152 shares in the last quarter. Finally, Covestor Ltd raised its holdings in shares of Envista by 34.2% in the 3rd quarter. Covestor Ltd now owns 6,359 shares of the company’s stock valued at $125,000 after buying an additional 1,621 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.